Literature DB >> 8150774

New directions for breast cancer therapeutic research.

M A Friedman1.   

Abstract

For the past two decades, attempts to improve chemotherapy for patients with breast cancer have emphasized the use of currently available agents. Research by drug discovery programs of the National Cancer Institute has identified a number of clinically promising novel agents. Conceivably, within the next several years there could be a doubling of the chemotherapy armamentarium for breast cancer--more than 30 active cytotoxic agents.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8150774

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  2 in total

1.  Phase II trial of piroxantrone in metastatic breast cancer. A Southwest Oncology Group study.

Authors:  P M Ravdin; S Green; J H Doroshow; S Martino
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

2.  Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast.

Authors:  P Hellemans; P A van Dam; M Geyskens; A T van Oosterom; P Buytaert; E Van Marck
Journal:  J Clin Pathol       Date:  1995-02       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.